BackLexaria Bioscience - Warrants (11/01/2026) Overview

Lexaria Bioscience - Warrants (11/01/2026) Total Assets

Lexaria Bioscience - Warrants (11/01/2026)'s total assets is $4.8M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$4.78M
29.07% YoYΔ $-1.96M vs prior year quarter

Peer trimmed avg / median

Loading

Lexaria Bioscience - Warrants (11/01/2026) Total Assets History

Loading

Lexaria Bioscience - Warrants (11/01/2026) vs. peers: Total Assets Comparison

Loading

Lexaria Bioscience - Warrants (11/01/2026) Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Lexaria Bioscience - Warrants (11/01/2026) (LEXXW) FAQ

Lexaria Bioscience - Warrants (11/01/2026)'s total assets stands at $4.8M as of May 2026. That compares with $6.7M in the prior-year period — down 29.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Lexaria Bioscience - Warrants (11/01/2026) reported $4.8M in total assets versus $6.7M a year earlier — a 29.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $6.7M in the prior-year period — down 29.1% year over year. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Lexaria Bioscience - Warrants (11/01/2026)'s total assets evolved across reporting periods, while the comparison chart places LEXXW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total assets is commonly used to spot outliers. Lexaria Bioscience - Warrants (11/01/2026)'s reading of $4.8M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.